London, UK – June 8, 2026
Engitix Ltd., a biotechnology company specializing in extracellular matrix (ECM)-driven drug discovery, has announced a strategic research collaboration and option agreement with GSK aimed at identifying and validating first-in-class therapeutic targets for liver fibrosis regression. The collaboration seeks to address one of the most significant unmet needs in chronic liver disease by focusing on the biological mechanisms that drive fibrosis reversal rather than merely slowing disease progression. By combining Engitix’s proprietary human ECM platform and extensive multi-omics datasets with GSK’s global drug development expertise, the companies aim to accelerate the discovery of innovative therapies capable of transforming treatment outcomes for patients suffering from liver fibrosis and related diseases.
A Novel Approach to Targeting Liver Fibrosis Regression
Liver fibrosis remains a major global health challenge and is a leading cause of chronic liver disease progression, cirrhosis, liver failure, and liver-related mortality. Despite significant advances in understanding the disease, effective therapies capable of actively reversing fibrosis remain limited. Under the new collaboration, Engitix will leverage its proprietary human ECM Platform, advanced disease models, and deeply phenotyped translational multi-omics datasets to uncover novel biological pathways associated with fibrosis resolution. Unlike traditional fibrosis research programs that focus primarily on preventing disease progression, this partnership is specifically designed to identify targets involved in fibrosis regression, offering the potential to develop truly disease-modifying treatments. The use of human tissue-derived models and real-world disease biology is expected to improve target validation and increase the likelihood of clinical success.
Combining Human Biology Insights with GSK’s Development Expertise
The strategic alliance combines Engitix’s innovative discovery capabilities with GSK’s extensive experience in translational science, drug development, and commercialization. Through the collaboration, Engitix will generate high-resolution datasets and functional assays that can identify and validate promising therapeutic targets linked to liver fibrosis resolution. GSK will have the option to license the resulting assays, datasets, and validated targets emerging from the research effort. Following target selection, GSK will lead further research, clinical development, regulatory activities, and commercialization efforts, leveraging its global infrastructure and expertise in liver disease. The partnership highlights the growing industry emphasis on integrating advanced biological datasets, human-centric disease models, and precision medicine approaches to accelerate the development of next-generation therapies.
Advertisement
Significant Financial and Strategic Value for Both Companies
The agreement also reflects the substantial commercial potential of fibrosis-targeted medicines. Under the terms of the deal, Engitix is eligible to receive up to £44.5 million in upfront and near-term payments, along with up to £118 million per target in downstream milestone payments. In addition, the company may earn tiered low-single-digit royalties on future product sales arising from the collaboration. Engitix Co-Founder and CEO Giuseppe Mazza, PhD, described the agreement as a significant milestone that validates the company’s ECM platform and its ability to capture the complex biology of fibrosis regression in human tissue. He emphasized that combining Engitix’s human-centric disease models with GSK’s development capabilities could enable the discovery of high-confidence targets with the potential to transform treatment options for patients with liver disease.
GSK’s Kaivan Khavandi, MD, PhD, Senior Vice President and Head of R&D for Respiratory, Immunology & Inflammation, noted that access to Engitix’s differentiated human biology platform and rich multi-omics datasets complements GSK’s internal capabilities and broader research network, supporting the company’s mission to develop differentiated fibrosis-targeted medicines for patients worldwide. As interest in fibrosis therapies continues to rise across the biopharmaceutical sector, the Engitix-GSK collaboration represents an important step toward unlocking new therapeutic opportunities and advancing the next generation of liver disease treatments.
Source: Engitix, GSK press release
